Related Experiment Video

Updated: Mar 8, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

E Leroy1, S N Constantinescu1

  • 1Christian de Duve Institute, Ludwig Institute for Cancer Research and Université catholique de Louvain, de Duve Institute, Brussels, Belgium.

Leukemia
|January 26, 2017
PubMed

Insights

Janus kinase 2 (JAK2) V617F mutation drives myeloproliferative neoplasms. Current inhibitors offer limited benefits; novel strategies are needed to develop targeted JAK2 inhibitors for improved MPN treatment and other diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Janus kinases (JAKs) are crucial for cytokine receptor signaling.
  • The JAK2 V617F mutation is prevalent in myeloproliferative neoplasms (MPNs).
  • Existing JAK2 inhibitors provide partial efficacy in MPNs and show potential in autoimmune diseases and cancer.

Purpose of the Study:

  • To review the current landscape of JAK2 inhibitor development.
  • To explore novel strategies for selecting JAK2 inhibitors based on structural insights.
  • To extend these approaches to other JAK family members.

Main Methods:

  • Review of recent advances in JAK2 structural biology.
  • Analysis of small-molecule targeting strategies for JAK2.
  • Exploration of inhibitor specificity (broad vs. narrow).

Main Results:

  • Current JAK2 inhibitors demonstrate positive but not curative effects.
  • Structural understanding facilitates the design of more effective inhibitors.
  • Novel approaches can guide the selection of inhibitors with tailored specificities.

Conclusions:

  • Targeting JAK2 remains critical for MPNs and other conditions.
  • Advances in structural biology and medicinal chemistry offer new avenues for JAK2 inhibitor development.
  • Developing inhibitors with specificities for normal vs. mutant JAK2, or across the JAK family, is a promising direction.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
12.0K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
94.3K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.3K